论文部分内容阅读
风湿病的传统治疗以激素和甲氨蝶呤为代表的改善病情药物为主,随着分子水平研究的深入,以肿瘤坏死因子α阻断剂为代表的多种靶向生物制剂进入临床。药物的选择性治疗必须依靠基因组及药物遗传学的研究,对不同患者疗效及药物毒副反应作个体化的分析,从而正确的选择药物。本文就风湿病的传统的甲氨蝶呤和TNF-α阻断剂在药物基因组学预测药物的疗效及副作用等进行综述。
The traditional treatment of rheumatism with hormones and methotrexate as the representative of the improvement of the disease-based drugs, with the molecular level of in-depth study, to tumor necrosis factor α blockers as the representative of a variety of targeted biological agents into the clinic. Selective treatment of drugs must rely on genomic and pharmacogenetical studies, the efficacy of different patients and drug side effects for individual analysis, and thus the correct choice of drugs. This article reviews the efficacy and side effects of traditional methotrexate and TNF-α blockers in rheumatoid arthritis predicted by pharmacogenomics.